New monographs are initiated based on clinical need, risk and usage, developed with key stakeholders and the approved by the British Pharmacopoeia Commission. Monographs are continuously reviewed by stakeholders and updated in new editions of the publication which are released annually.  

The BP Secretariat prepares monographs by working with:

• market authorisation holders (MAHs)
• other pharmacopoeias
• the BP Commission (BPC) and its expert advisory groups (EAGs), panels of experts and working parties
• the BP Laboratory
• interested parties

The process of monograph development